Docoh
Loading...

FENC Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation in the U.S. for this potential use. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans.

Company profile

Ticker
FENC
Exchange
CEO
Rostislav Raykov
Employees
Location
Fiscal year end
Former names
ADHEREX TECHNOLOGIES INC
SEC CIK
Subsidiaries
Oxiquant, Inc. • Cadherin Biomedical Inc. • Fennec Pharmaceuticals (EU) Limited ...

FENC stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 Aug 21
23 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 27.29M 27.29M 27.29M 27.29M 27.29M 27.29M
Cash burn (monthly) (positive/no burn) 953K 1.31M 1.5M 1.48M 1.4M
Cash used (since last report) n/a 3.61M 4.94M 5.69M 5.58M 5.28M
Cash remaining n/a 23.69M 22.35M 21.6M 21.71M 22.01M
Runway (months of cash) n/a 24.9 17.1 14.4 14.7 15.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
21 Oct 21 Rallis Chris A Common Shares Option exercise Acquire M No No 1.5 3,333 5K 3,333
29 Jun 21 Marco Maria Brughera Stock Option Common Shares Grant Acquire A No No 7.52 20,000 150.4K 20,000
29 Jun 21 Jodi A Cook Stock Option Common Shares Grant Acquire A No No 7.52 20,000 150.4K 20,000
29 Jun 21 Adrian Haigh Stock Option Common Shares Grant Acquire A No No 7.52 20,000 150.4K 20,000
29 Jun 21 Rallis Chris A Stock Option Common Shares Grant Acquire A No No 7.52 20,000 150.4K 20,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

46.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 40 52 -23.1%
Opened positions 12 5 +140.0%
Closed positions 24 5 +380.0%
Increased positions 7 13 -46.2%
Reduced positions 16 20 -20.0%
13F shares
Current Prev Q Change
Total value 90.84M 106.61M -14.8%
Total shares 12.08M 14.37M -16.0%
Total puts 0 0
Total calls 48.1K 0 NEW
Total put/call ratio
Largest owners
Shares Value Change
Southpoint Capital Advisors 4.08M $29.72M 0.0%
Sonic Fund II 2.43M $17.74M 0.0%
Avoro Capital Advisors 1.67M $12.17M 0.0%
683 Capital Management 1.11M $8.09M 0.0%
Solas Capital Management 867.86K $6.33M +8.5%
DG Capital Management 588.77K $4.29M NEW
Millennium Management 404.77K $2.95M NEW
Harbert Fund Advisors 120.85K $881K NEW
Russell Investments 112.58K $820K -42.7%
Ergoteles 92.34K $673K NEW
Largest transactions
Shares Bought/sold Change
BLK Blackrock 62.49K -1.07M -94.5%
Eventide Asset Managment 0 -1.04M EXIT
DG Capital Management 588.77K +588.77K NEW
Millennium Management 404.77K +404.77K NEW
STT State Street 0 -327.15K EXIT
Granahan Investment Management 0 -217.3K EXIT
WFC Wells Fargo & Co. 1.4K -184.51K -99.2%
NTRS Northern Trust 0 -182.11K EXIT
Geode Capital Management 17.93K -151.43K -89.4%
Harbert Fund Advisors 120.85K +120.85K NEW

Financial report summary

?
Competition
PfizerAMGENAstrazenecaRocheNovartisMerck KGaA
Management Discussion
  • Research and development expenses decreased by $321 for the three months ended June 30, 2021 compared to the same period in 2020 as the Company’s development activities shifted back to product launch readiness and pre-commercial development of PEDMARKTM.  General and administrative expenses decreased by $604 compared to same period in 2020. On June 30, 2020, the Company was relatively much closer to the anticipated launch date than it is in 2021. We would anticipate the same increase in pre commercialization activities as we near the 2021 launch date. The reduction in general and administrative expenses was slightly offset by higher expenses associated with additional employees and the increase in non-cash equity remuneration expense for employees and board members related to the vesting of new and existing grants.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: attached, burn, calculated, closer, copy, default, drew, Exhibit, forfeited, furnished, inflow, insolvency, long, multiplied, pre, prepayment, RSU, slightly, trailing, unpaid
Removed: asset, continued, director, legal, listing, thousand